东阳光长江药业(01558)下跌5.27%,报9.89元/股

金融界
19 Dec 2024

12月19日,东阳光长江药业(01558)盘中下跌5.27%,截至13:13,报9.89元/股,成交2023.29万元。

宜昌东阳光长江药业股份有限公司是一家专注于抗病毒、内分泌及代谢性疾病、心血管疾病等治疗领域产品的开发、生产与销售的制药企业,公司产品在中国市场占据重要地位,其中产品磷酸奥司他韦颗粒剂是中国市场唯一的生产商。根据标点医药提供的数据,公司在2014年进入抗流感病毒产品市场前四强,而在2013年和2014年,公司磷酸奥司他韦产品的销量在中国区名列前茅。

截至2024年中报,东阳光长江药业营业总收入24.55亿元、净利润6.85亿元。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10